Advertisement

Vitiligo pp 11-23 | Cite as

Definitions and Classification

  • Alain TaïebEmail author
  • Mauro Picardo
Chapter

Abstract

Since the first edition of this textbook, the nomenclature has been revised after an extensive international work within the Vitiligo Global Issues Consensus Conference (VGICC). Vitiligo/nonsegmental vitiligo (NSV) is a consensus umbrella term for all forms of generalized vitiligo. It is an acquired chronic pigmentation disorder characterized by white patches, often symmetrical, which usually increases in size with time, corresponding to a substantial loss of functioning epidermal and sometimes hair follicle melanocytes. The two other subsets of vitiligo defined by the international consensus are segmental vitiligo and unclassified/undetermined vitiligo which correspond to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy.

References

  1. 1.
    Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27–35.CrossRefGoogle Scholar
  2. 2.
    Koga M. Vitiligo: a new classification and therapy. Br J Dermatol. 1977;97:255–61.CrossRefGoogle Scholar
  3. 3.
    Gauthier Y, Cario-Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16:322–32.CrossRefGoogle Scholar
  4. 4.
    Mulekar SV, Al Issa A, Asaad M, et al. Mixed vitiligo. J Cutan Med Surg. 2006;10:104–7.CrossRefGoogle Scholar
  5. 5.
    Ezzedine K, Amazan E, Séneschal J, Cario-André M, Léauté-Labrèze C, Vergier B, Boralevi F, Taieb A. Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res. 2012;25:527–9.CrossRefGoogle Scholar
  6. 6.
    Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1–13.CrossRefGoogle Scholar
  7. 7.
    Ezzedine K, Mahé A, van Geel N, Cardot-Leccia N, Gauthier Y, Descamps V, Al Issa A, Ly F, Chosidow O, Taïeb A, Passeron T. Hypochromic vitiligo: delineation of a new entity. Br J Dermatol. 2015;172:716–21.CrossRefGoogle Scholar
  8. 8.
    Gan EY, Cario-André M, Pain C, Goussot JF, Taïeb A, Seneschal J, Ezzedine K. Follicular vitiligo: a report of 8 cases. J Am Acad Dermatol. 2016;74:1178–84.CrossRefGoogle Scholar
  9. 9.
    Berger TG, Kiesewetter F, Maczek C, et al. Psoriasis confined strictly to vitiligo areas--a Koebner-like phenomenon? J Eur Acad Dermatol Venereol. 2006;20:178–83.CrossRefGoogle Scholar
  10. 10.
    Singh ZN, Tretiakova MS, Shea CR, Petronic-Rosic VM. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol. 2006;19:1255–60.CrossRefGoogle Scholar
  11. 11.
    Hartmann A, Bedenk C, Keikavoussi P, et al. Vitiligo and melanoma-associated hypopigmentation (MAH):shared and discriminative features. J Dtsch Dermatol Ges. 2008;6:1053–9.CrossRefGoogle Scholar
  12. 12.
    Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.CrossRefGoogle Scholar
  13. 13.
    Thoma W, Krämer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005;19:147–52.CrossRefGoogle Scholar
  14. 14.
    Guillet G, Helenon R, Gauthier Y, et al. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol. 1988;15:286–9.CrossRefGoogle Scholar
  15. 15.
    Relyveld GN, Dingemans KP, Menke HE, et al. Ultrastructural findings in progressive macular hypomelanosis indicate decreased melanin production. J Eur Acad Dermatol Venereol. 2008;22:568–74.CrossRefGoogle Scholar
  16. 16.
    Westerhof W, Relyveld GN, Kingswijk MM, et al. Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Arch Dermatol. 2004;140:210–4.CrossRefGoogle Scholar
  17. 17.
    Oplatek A, Brown K, Sen S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27:26–33.CrossRefGoogle Scholar
  18. 18.
    Smith DA, Burgdorf WH. Universal cutaneous depigmentation following phenytoin-induced toxic epidermal necrolysis. J Am Acad Dermatol. 1984;10:106–9.CrossRefGoogle Scholar
  19. 19.
    Boissy RE, Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res. 2004;17:208–14.CrossRefGoogle Scholar
  20. 20.
    Cario-André M, Ardilouze L, Pain C, et al. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol. 2006;155:493–4.CrossRefGoogle Scholar
  21. 21.
    Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol. 2008;33:74–6.PubMedGoogle Scholar
  22. 22.
    Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35:671–4.CrossRefGoogle Scholar
  23. 23.
    Lee HS, Chun YS, Hann SK. Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol. 1999;40:21–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospitals, and INSERM U 1035University of BordeauxBordeauxFrance
  2. 2.Cutaneous Physiopathology and CIRMSan Gallicano Dermatological Institute, IRCCSRomeItaly

Personalised recommendations